Medicare coverage for a costly, but controversial, new Alzheimer’s drug will go only to people enrolled in approved clinical trials despite FDA endorsement of the medication.
View original article
Contributor: Lenny Bernstein
Medicare coverage for a costly, but controversial, new Alzheimer’s drug will go only to people enrolled in approved clinical trials despite FDA endorsement of the medication.
View original article
Contributor: Lenny Bernstein